The influence of C-reactive protein on depression in inflammatory bowel disease: A systematic review and meta-analysis.

J Affect DisordApr 24, 2026 (epub)
Clinical ResearchGastroenterologyPsychiatry

Yidan Cheng, Meifen Song, Pingyang Xu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between C-reactive protein (CRP) levels and depression in patients with inflammatory bowel disease (IBD). Analyzing data from 10 case-control studies with 2105 participants, it was found that IBD patients with depression had significantly higher CRP levels than non-depressed patients (SMD = 0.18, 95% CI: 0.09-0.27).

Key findings

  • IBD patients with depression had significantly higher CRP levels than non-depressed patients (SMD = 0.18, 95% CI: 0.09-0.27).
  • The association was more pronounced in the Asian region (SMD = 0.26, 95% CI: 0.11-0.41).
  • In patients aged ≤40 years, the association was stronger (SMD = 0.27, 95% CI: 0.15-0.39).
  • Higher CRP levels were linked to a greater likelihood of depression in IBD patients.

Why it matters

Understanding the link between CRP levels and depression in IBD patients can aid clinicians in identifying those at higher risk for depression, potentially leading to improved management strategies for this comorbidity.

Source

PubMed · PMID 42035803

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.